ArticleAnnals of surgical oncology2026
National Evaluation of the Management of Melanoma Patients with Multiple Positive Sentinel Lymph Nodes.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
introductionClinical trials for melanoma patients demonstrated safety of observation in lieu of completion lymph node dissection (CLND) following positive sentinel lymph node (SLN) biopsy. Patients with two or more positive SLNs were infrequently included in the trials, leaving uncertainty about their management. We aimed to (1) assess national trends of CLND use in patients with two or more positive SLNs; (2) examine factors associated with CLND use; and (3) examine overall survival outcomes.
methodsPatients with stage I-III melanoma who underwent SLN biopsy between 2012 and 2021 were identified from the National Cancer Database. Factors associated with CLND were assessed by hierarchical logistic regression. Overall survival was estimated using Cox proportional hazards models.
resultsAmong 151,442 patients (median age 61 years; 41.3% female) who underwent SLN biopsy, 5440 (3.6%) had two or more positive SLNs. CLND in patients with two or more positive SLNs decreased from 73% in 2012 to 14% in 2021, while immunotherapy utilization increased from 38% in 2012 to 76% in 2021. Patients with two or more positive SLNs were more likely to undergo CLND if they had melanoma in the head/neck region (odds ratio [OR] 2.02, 95% confidence interval [CI] 1.39-2.95) or ulcerated lesions (OR 1.42, 95% CI 1.11-1.83). There was no difference in 3-year overall survival (70.5% for two or more positive SLNs with observation vs. 70.8% for two or more positive SLNs with CLND; hazard ratio 1.03, 95% CI 0.77-1.37) for observation vs. CLND.
conclusionUtilization of CLND declined for melanoma patients with two or more positive SLNs following major clinical trials, with no difference in overall survival for observation versus CLND. Evolving treatment recommendations have been rapidly incorporated into practice in the United States.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.